Lantus and Injection site inflammation - a phase IV clinical study of FDA data

Summary:

Injection site inflammation is reported as a side effect among people who take Lantus (insulin glargine recombinant), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Metformin, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Injection site inflammation when taking Lantus. It is created by eHealthMe based on reports of 190,478 people who have side effects when taking Lantus from the FDA, and is updated regularly.

What is Lantus?

Lantus has active ingredients of insulin glargine recombinant. It is often used in diabetes. eHealthMe is studying from 191,782 Lantus users. Check the latest studies of Lantus.

What is Injection site inflammation?

Injection site inflammation is found to be associated with 404 drugs and 431 conditions by eHealthMe. Check the latest studies of Injection site inflammation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

190,478 people reported to have side effects when taking Lantus.
Among them, 55 people (0.03%) have Injection site inflammation.

Could Lantus cause Injection site inflammation?

Among these 55 people:

How long have people been on Lantus when they have Injection site inflammation? *

What is the gender of people who have Injection site inflammation when taking Lantus? *

female: 67.27 %
male: 32.73 %

What is the age of people who have Injection site inflammation when taking Lantus? *

What are other drugs people take besides Lantus? *

What are other side effects people have besides Injection site inflammation? *

Injection Site Erythema (redness at injection site): 21 people, 38.18%
Injection Site Pain: 19 people, 34.55%
Injection Site Pruritus (severe itching at injection site): 12 people, 21.82%
Injection Site Swelling: 12 people, 21.82%
Blood Glucose Increased: 11 people, 20.00%
Injection Site Mass: 7 people, 12.73%
Injection Site Reaction: 7 people, 12.73%
Pain: 7 people, 12.73%
Injection Site Haemorrhage (bleeding from injection site): 6 people, 10.91%
Injection Site Nodule (small swelling or aggregation of cells in the body, esp. an abnormal one at injection site): 6 people, 10.91%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 9.09%
High Blood Pressure: 4 people, 7.27%
Asthma: 3 people, 5.45%
Bipolar Disorder (mood disorder): 3 people, 5.45%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 3 people, 5.45%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 3 people, 5.45%
Diabetic Hyperosmolar Coma (diabetes coma due to extremely high blood sugar (glucose) levels; extreme lack of water (dehydration)): 3 people, 5.45%
Stress And Anxiety: 3 people, 5.45%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 3.64%
Thyroid Diseases: 1 person, 1.82%

* Approximation only. Some reports may have incomplete information.

Do you take Lantus and have Injection site inflammation?

- Check whether Injection site inflammation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lantus:

Lantus (191,782 reports)

Browse all side effects of Lantus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site inflammation:

Injection site inflammation (404 drugs)

Browse all the conditions that are associated with Injection site inflammation:

Injection site inflammation (431 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on insulin glargine recombinant (the active ingredients of Lantus) and Lantus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.